/
index.html
314 lines (299 loc) · 16.1 KB
/
index.html
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1">
<meta name="description" content="">
<meta name="author" content="">
<title>Viralchemy Inc</title>
<link href="static/bootstrap/css/bootstrap.css" rel="stylesheet">
<link href="static/fontawesome/css/font-awesome.min.css" rel="stylesheet">
<link href="static/css/landing.css" type="text/css" rel="stylesheet">
<!-- Custom Fonts -->
<link href="https://fonts.googleapis.com/css?family=Lora:400,700,400italic,700italic" rel="stylesheet" type="text/css">
<link href="https://fonts.googleapis.com/css?family=Montserrat:400,700" rel="stylesheet" type="text/css">
<!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
<!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
<!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
<script src="https://oss.maxcdn.com/libs/respond.js/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body id="page-top" data-spy="scroll" data-target=".navbar-fixed-top">
<!-- Navigation -->
<nav class="navbar navbar-custom navbar-fixed-top" role="navigation">
<div class="container">
<div class="navbar-header">
<button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-main-collapse">
<i class="fa fa-bars"></i>
</button>
<a class="navbar-brand page-scroll" href="#page-top">Viralchemy</a>
</div>
<div class="collapse navbar-collapse navbar-right navbar-main-collapse">
<ul class="nav navbar-nav">
<li class="hidden">
<a href="#page-top"></a>
</li>
<li>
<a class="page-scroll" href="#about">About</a>
</li>
<li>
<a class="page-scroll" href="#team">Team</a>
</li>
<li>
<a class="page-scroll" href="#opportunity">Opportunity</a>
</li>
<li>
<a class="page-scroll" href="#technology">Technology</a>
</li>
<li>
<a class="page-scroll" href="#contact">Contact</a>
</li>
</ul>
</div>
<!-- /.navbar-collapse -->
</div>
<!-- /.container -->
</nav>
<!-- Intro Header -->
<header class="intro" style='padding-top:0px'>
<div class="intro-body">
<div class="container">
<div class="row">
<div class="intro-box col-md-10 col-md-offset-1">
<!-- h1 class="brand-heading" style='color:white !important;margin-bottom:6px'>Technically diverse. Unified motivation. Driven to do good.</h1 -->
<div class="intro-text">
Vi<sup>ralchemy</sup> is committed to improving human health through the
synergy of bioscience, creativity, and technology to innovate actionable
therapeutics for diseases of unmet need.
</div>
</div>
</div>
</div>
</div>
</header>
<section id="about" class="content-section">
<div class="container">
<div class="row">
<div class="col-md-12 ">
<h2>About</h2>
<p>
Vi<sup>ralchemy</sup> Inc. is a privately held, preclinical stage
biopharmaceutical company. Our goal is improving the health of all people
through the discovery and development of treatments for emerging viral diseases
neglected by the current pharmaceutical paradigm.
</p>
</div>
</div>
</div>
</section>
<section id="team" class="container content-section">
<div class="row">
<div class="col-md-12">
<h2>Team</h2>
<h3>Management</h3>
<div class="tagline">Technically diverse. Unified motivation. Innovative results</div>
<div class="row management">
<div class="col-sm-6 col-md-2">
<div class="thumbnail">
<div class="caption">
<span class="name">Trevor V. Gale, Ph.D.</span><br />
Co-Founder <br />
</div>
</div>
</div>
<div class="col-sm-6 col-md-2">
<div class="thumbnail">
<div class="caption">
<span class="name">Timothy M. Horton, M.S.</span><br />
Co-Founder <br />
</div>
</div>
</div>
<div class="col-sm-6 col-md-2">
<div class="thumbnail">
<div class="caption">
<span class="name">Ben T. Bradley, M.D., Ph.D.</span><br />
Co-Founder <br />
</div>
</div>
</div>
<div class="col-sm-6 col-md-2">
<div class="thumbnail">
<div class="caption">
<span class="name">Andrew R. Hoffmann, B.S.</span><br />
Co-Founder <br />
</div>
</div>
</div>
<div class="col-sm-6 col-md-2">
<div class="thumbnail">
<div class="caption">
<span class="name">Ryan M. Hanson, MBA, M.S. </span><br />
</div>
</div>
</div>
</div>
<h3>Scientific Advisory</h3>
<div class="row">
<div class="col-sm-6 col-md-3">
<div class="thumbnail">
<div class="caption">
<span class="name">Robert Garry, Ph.D.</span><br />
Professor, Tulane University School of Medicine<br />
Program Manager, Viral Hemorrhagic Fever Consortium<br />
Co-Founder, Zalgen Labs<br />
</div>
</div>
</div>
<div class="col-sm-6 col-md-3">
<div class="thumbnail">
<div class="caption">
<span class="name">William Wimley, Ph.D.</span><br />
Professor, Tulane University School of Medicine<br />
</div>
</div>
</div>
</div>
<h3>Strategic Advisory</h3>
<div class="row">
<div class="col-sm-6 col-md-3">
<div class="thumbnail">
<div class="caption">
<span class="name">Tobin Dickerson, Ph.D.</span><br />
Professor, The Scripps Research Institute Department of Chemistry<br />
Co-Founder and Chief Scientific Officer, MiNDERA
</div>
</div>
</div>
<div class="col-sm-6 col-md-3">
<div class="thumbnail">
<div class="caption">
<span class="name">Ryan Boggs, CPA/ABV</span><br />
Ryan Boggs, CPA/ABV
</div>
</div>
</div>
</div>
</div>
</div>
</section>
<section id="opportunity" class="content-section">
<div class="container">
<div class="row">
<div class="col-md-12">
<h2>Opportunities...</h2>
<p>
Dengue virus has an enormous world-wide impact. Half of the global population resides in locales with dengue virus transmission.
</p>
<p><iframe border="0" src="http://www.healthmap.org/dengue/en/" width="100%" height="500px"></iframe></p>
<p>
Annually, there are over 55 million cases of disease with 38 million
necessitating medical intervention and upwards of 20,000 deaths. In 2015, a
tetravalent vaccine was approved for community administration. Despite this
important first step towards disease control, there remains an unquestionable
need for a specific pharmaceutical treatment for dengue fever. Multiple
variables offer evidence for this need: the cautious vaccination approach
recommended by the World Health Organization, sustained economic burden of
dengue fever, and continued incidence of severe disease. While global mortality
from most communicable diseases decreased, dengue fever deaths increased 48%
over the last decade. Sadly those most likely to benefit from a specific
treatment are most often our most vulnerable population: pediatric patients.
Dengue has a disproportionately negative effect on children; the likelihood of
severe disease, hospitalization, and fatal outcome increases in pediatric
patients. Age notwithstanding, the average inpatient hospital stay for dengue
fever, dengue hemorrhagic fever, and dengue shock syndrome is ~5 days. While
hospitalization rates vary (~25% all symptomatic cases), one reality of the
cost of dengue is certain: of the global $8.9 billion annual economic burden,
hospitalization accounts for the highest direct cost. At Vi<sup>ralchemy</sup>
we recognize the human toll exacted by dengue virus and acknowledge both the
humanitarian and economic potential held by a pharmaceutical treatment that
alleviates this disease. We are developing such a treatment.
</p>
<h3>...and Solutions</h3>
<p>
There is currently no approved treatment for dengue fever. As such, the current
standard of care involves non-specific, supportive therapy with careful fluid
management and pain control. This clinical approach addresses the symptom
without treating the cause of the disease. Vi<sup>ralchemy</sup>'s goal is to
address this gap in care by developing an antiviral therapy against dengue for
use by global healthcare providers. Ideally our therapy will be administered
immediately upon disease recognition/symptom onset in conjunction with a
molecular diagnostic. Our product acts directly on the virus at two distinct
stages of the replication cycle, halting disease progression and, consequently,
harboring potential to mitigate hospitalization of dengue fever patients.
</p>
</div>
</div>
</div>
</section>
<section id="technology" class="content-section">
<div class="container">
<div class="row">
<div class="col-md-12">
<h2>Technology & Pipeline</h2>
<p>
Viruses have two critical stages in their life cycle: infection and
replication. Infection encompasses the physical contact between, and entry of,
a virus and host cell. Replication features production of more virus within the
infected cell, carried out by host and viral machinery. Vi<sup>ralchemy</sup>'s
antiviral formulation addresses both stages of viral replication. Our lead
therapeutic candidate combines a small molecule and synthetic polypeptide; each
individual component possesses antiviral activity, though at distinct stages of
the viral replication cycle. The small molecule targets a host factor pertinent
to viral replication, leveraging the cell penetrating power of small molecules.
Vi<sup>ralchemy</sup>'s proprietary peptides—while not synonymous with
antibodies—sequester viral particles outside of cells, recapitulating
mechanistic properties of antibodies by abrogating subsequent infectivity. The
synergistic activity of the small molecule and polypeptide results in a robust
antiviral strategy exhibiting virtually no toxicity. Further, as an inherent
characteristic of targeting conserved factors, our broad-spectrum antiviral
agent (BSAA) products will offer rapid therapeutic portfolio expansion.
</p>
<img src="static/img/pipeline.png" alt="Pipeline graphic" />
</div>
</div>
</div>
</section>
<section id="contact" class="content-section">
<div class="container">
<div class="row">
<div class="col-md-12">
<div class="social pull-right">
<a href="https://twitter.com/viralchemyinc" target="_blank"><i class="fa fa-twitter-square fa-10" aria-hidden="true"></i></a>
<a href="https://www.linkedin.com/company/viruachemyinc" target="_blank"><i class="fa fa-linkedin-square fa-10" aria-hidden="true"></i></a>
</div>
<h2>Contact</h2>
<div class="address">
<!--
Address <br />
City, State Zip <br />
-->
<div class="email"><i class="fa fa-envelope-open fa-10" aria-hidden="true"> </i><a href="mailto:info@viralchemy.com">info@viralchemy.com</a></div>
</div>
</div>
</div>
</div>
</section>
<footer>
<div class="container">
<div class="copy">© 2017-2018 Viralchemy Inc. All rights reserved</div>
</div>
</footer>
<!-- Footer -->
<script src="static/js/jquery-1.11.0.min.js"></script>
<script src="static/bootstrap/js/bootstrap.min.js"></script>
<script src="static/js/jquery.easing.min.js"></script>
<script src="static/js/script.js"></script>
<script src="static/js/holder.min.js"></script>
<script>
(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,'script','https://www.google-analytics.com/analytics.js','ga');
ga('create', 'UA-84215305-1', 'auto');
ga('send', 'pageview');
</script>
</body>
</html>